Taxol News and Research

RSS

Taxol is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Taxol is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called paclitaxel.

New insight into how our body cells block the development of cancer

Scientists at the Medical Research Council (MRC) Cancer Cell Unit, at the University of Cambridge, have revealed a new insight into how our body cells block the development of cancer.

11 Nov 2004

Broccoli, cauliflower and cabbage effective in disrupting late stages of cell growth in breast cancer

A well known anti-cancer agent in certain vegetables has just had its reputation enhanced. The compound, in broccoli and other cruciferous vegetables, has been found to be effective in disrupting late stages of cell growth in breast cancer.

1 Sep 2004

Dual-action compound shows promise in killing prostate cancer cells

Ohio State University researchers are working on developing a multi-purpose cancer drug that might one day scale back the number of medications some cancer patients need to take.

22 Aug 2004

Researchers map structure of anti-cancer molecule and open the door to the creation of more effective cancer treatments

Scientists at Emory University, in collaboration with researchers at three national laboratories, have solved the structural puzzle of how an emerging class of promising cancer drugs works to halt cell division. The discovery potentially opens the door to the creation of more effective cancer treatments.

13 Aug 2004

Promising families of drugs combat the spread of tumors in different ways

Pharmaceutical companies seeking to design more effective cancer chemotherapy agents may have an easier road ahead than was previously believed.

9 Aug 2004

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

A drug derived from an ocean-growing sponge helps prevent the growth of cancer cells

A drug derived from an ocean-growing sponge teams up to enhance the performance of the yew tree derivative Taxol® (paclitaxel) in preventing the growth of cancer cells, according to research published in the July 15 issue of the journal Cancer Research.

15 Jul 2004

Natural products to be developed as anti-cancer therapeutics

The licence grants Zentaris exclusive worldwide rights for the development, manufacture and marketing of disorazoles, a novel class of natural products with strong anti-cancer potential discovered by GBF researchers.

8 Jul 2004

Chemotherapy agents as well as the newest biologic and targeted cancer therapy drugs, can harm a patient’s heart

Cancer treatments, including the most commonly used chemotherapy agents as well as the newest biologic and targeted therapy drugs, can harm a patient’s heart, sometimes fatally

29 Jun 2004

European Commission has approved the use of Herceptin® (trastuzumab) in combination with Taxotere®

The approval is based on study results which showed that for women with HER2-positive breast cancer, the combination of Herceptin and Taxotere significantly improved median life expectancy by more than one-third (31 months with Herceptin plus Taxotere vs. 22 months for Taxotere alone).

23 Jun 2004

Paclitaxel analog kills more cancer cells than natural product

Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.

21 Jun 2004

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).

15 Jun 2004